AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
Category: #health  By Nikita Chaurasia  Date: 2019-02-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
  • The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial
  • Anti-Tau monoclonal antibody was detected and improved under the collaboration between AC Immune and Genentech

The Switzerland-based clinical-stage biopharmaceutical company AC Immune has reportedly declared that Genentech has commenced enrollment of patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, called as MTAU9937A, RO7105705, developed to treat moderate Alzheimer’s disease.

As per trusted sources, the same antibody is also being assessed by Genentech in a different Phase 2 trial to measure it safety and efficacy in patients with prodromal-to-mild Alzheimer's disease.

Chief Executive Officer of AC Immune, Professor Andrea Pfeifer was reportedly quoted saying that the company is highly encouraged owing to the fact the Genentech is expanding its clinical assessment of AC Immune’s anti-Tau antibody. The interest to target Tau was recently shown by the company’s newest collaboration with Eli Lilly which was formed in early January to develop small molecule Tau MorphomerTM to treat Alzheimer’s, Pfeifer further added.

Reportedly, these projects demonstrate the scientific leadership of AC Immune in the field and are a significant part of its broad portfolio of three product candidates in Phase 2 clinical testing, an increasingly visible focus on early projects targeting neuro-inflammation and neuro-orphan indications, and additional diagnostics in clinical development.

According to a press release by AC Immune, the development of the monoclonal antibody is an important aspect of the partnership the company formed with Genentech in the year 2012 to market the monoclonal humanized antibodies against Tau protein. Reportedly, the monoclonal antibody was detected and improved under the collaboration between AC Immune and Genentech.

For the record, Tau pathology spreads with a distinctive spatiotemporal pattern in the brain, coinciding with both disease progression and clinical symptoms in Alzheimer’s disease.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Japan’s SoftBank amid plans to invest in venture capital funds
Japan’s SoftBank amid plans to invest in venture capital funds
By Nikita Chaurasia

The conglomerate plans to mark its presence in Latin America by investing in venture capital funds, with a strategy to deploy nearly $500 million in five to 10 funds. SoftBank Group Corp., a multinational conglomerate based out of Tokyo, reportedly ...

TG Manufacturing acquires contract manufacturing firm TurnKey
TG Manufacturing acquires contract manufacturing firm TurnKey
By Nikita Chaurasia

TurnKey presently supplies a varied group of consumers in the industrial laboratory, defense and gaming industries among others. Using TGM’s advanced manufacturing technology, quality systems and global network and combining them with TurnKe...

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
By Nikita Chaurasia

12 patients with DME have enrolled into the study.   The results for the Phase 1 trial will be out by the end of 2019. Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic...